These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38369231)
1. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model. Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231 [TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Xue K; MacLaren RE Expert Opin Investig Drugs; 2020 Oct; 29(10):1163-1170. PubMed ID: 32741234 [TBL] [Abstract][Full Text] [Related]
3. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences. Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281 [TBL] [Abstract][Full Text] [Related]
4. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides. Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121 [TBL] [Abstract][Full Text] [Related]
5. mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway. Liang XH; Nichols JG; Hsu CW; Vickers TA; Crooke ST Nucleic Acids Res; 2019 Jul; 47(13):6900-6916. PubMed ID: 31165876 [TBL] [Abstract][Full Text] [Related]
6. Applications of antisense oligonucleotides for the treatment of inherited retinal diseases. Collin RW; Garanto A Curr Opin Ophthalmol; 2017 May; 28(3):260-266. PubMed ID: 28151748 [TBL] [Abstract][Full Text] [Related]
7. RNA-based therapies in inherited retinal diseases. Girach A; Audo I; Birch DG; Huckfeldt RM; Lam BL; Leroy BP; Michaelides M; Russell SR; Sallum JMF; Stingl K; Tsang SH; Yang P Ther Adv Ophthalmol; 2022; 14():25158414221134602. PubMed ID: 36388727 [TBL] [Abstract][Full Text] [Related]
8. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides. Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362 [TBL] [Abstract][Full Text] [Related]
9. Effects of combinations of gapmer antisense oligonucleotides on the target reduction. Yanagidaira M; Yoshioka K; Nagata T; Nakao S; Miyata K; Yokota T Mol Biol Rep; 2023 Apr; 50(4):3539-3546. PubMed ID: 36787053 [TBL] [Abstract][Full Text] [Related]
10. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Wheeler TM; Leger AJ; Pandey SK; MacLeod AR; Nakamori M; Cheng SH; Wentworth BM; Bennett CF; Thornton CA Nature; 2012 Aug; 488(7409):111-5. PubMed ID: 22859208 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells. Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814 [TBL] [Abstract][Full Text] [Related]
12. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides. Ward AJ; Norrbom M; Chun S; Bennett CF; Rigo F Nucleic Acids Res; 2014 May; 42(9):5871-9. PubMed ID: 24589581 [TBL] [Abstract][Full Text] [Related]
13. Bestrophin1: A Gene that Causes Many Diseases. Smith JJ; Nommiste B; Carr AF Adv Exp Med Biol; 2019; 1185():419-423. PubMed ID: 31884648 [TBL] [Abstract][Full Text] [Related]
14. Gene therapy for inherited retinal diseases: progress and possibilities. Hu ML; Edwards TL; O'Hare F; Hickey DG; Wang JH; Liu Z; Ayton LN Clin Exp Optom; 2021 May; 104(4):444-454. PubMed ID: 33689657 [TBL] [Abstract][Full Text] [Related]